Vanguard Group Inc Recursion Pharmaceuticals, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RXRX
# of Institutions
365Shares Held
286MCall Options Held
3.28MPut Options Held
3.16M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl34.8MShares$174 Million1.99% of portfolio
-
Baillie Gifford & CO24.4MShares$122 Million0.12% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$86.6 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$73.3 Million0.27% of portfolio
-
Kinnevik Ab (Publ) Stockholm, V713.4MShares$67.2 Million100.0% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $902M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...